Antibody Technologies
We are a research group specializing in antibody technologies, with core expertise in antibody discovery, protein engineering, and synthetic biology. We work with multiple protein scaffolds, including human antibodies, nanobodies, and other engineered binding proteins. These precision molecules are developed and applied to address challenges in diagnostics, therapeutics, microbiome engineering, and industrial biotechnology. Our research is guided by the belief that science should serve society. To that end, we pursue projects that generate both fundamental insight and practical impact, with an emphasis on translational potential and real-world applications. We are also strongly committed to innovation and entrepreneurship, and we have successfully spun out several biotech companies.
Research focus
Our technological platform is centered on the development of monoclonal antibodies and nanobodies with unique binding properties, oligoclonal mixtures of antibodies and nanobodies, and designed antigens tailored for vaccine development and specialized antibody discovery. These molecular formats are engineered to achieve broad-spectrum neutralization at low doses, enable selective targeting of disease-relevant factors, retain high-affinity binding under harsh industrial or physiological conditions, and be manufactured at ultra-low cost. We view antibodies and antigens as modular bioengineering tools that can be used to design molecules with highly specific functionality, capable of operating in complex biological environments. This enables the development of advanced biotherapeutics, diagnostic platforms, and molecular tools for applications across the feed, food, and biocontrol sectors.
Our motivation and mission
We are driven by the urgent need for innovative molecular solutions to address global challenges such as drug and antibiotic resistance, the spread of pathogens, and food security. These issues will shape human and planetary health for decades to come and require technologies that are both accessible and robust. Our group has already contributed to critical advances in areas including recombinant antivenom development, cost-effective binding proteins, and next-generation antibody discovery platforms. We strive not only to innovate, but also to empower other researchers by developing tools and strategies that are scalable, adaptable, and easy to integrate into existing pipelines.
